% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • confucius_say_this confucius_say_this Apr 24, 2013 7:03 AM Flag

    A Tangled web of deceit and lies - and the Geron shareholders are the suckers financing it!

    Asterias Biotherapeutics, Inc., a development stage biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.

    230 Constitution Drive

    Menlo Park, CA 94025

    United States

    Founded in 2012

    5 Employees

    Key Executives for Asterias Biotherapeutics, Inc
    Dr. Thomas B. Okarma
    Chief Executive Officer
    Age: 66 Mr. Peter S. Garcia
    Chief Financial Officer and Principal Accounting Officer
    Age: 50 Dr. Katharine E. Spink
    Chief Operating Officer and Vice President
    Age: 37 Dr. Jane S. Lebkowski
    President of Research and Development
    Age: 56 Dr. Edward D. Wirth
    Chief Translational Officer
    Age: 48

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lebkowski, Wirth and Okarma - the trio who worked to-gather to fool us shareholders to acquire all intellectual assets of Asterias while at Geron at our cost while they pocketed hefty salaries and cheaply acquired bonus shares!! What did Huh and Scarlett get? All bunch of crooks!!

      • 1 Reply to mruyog
      • SP was $5+ when Okarma "left" and now look where it is. At least he is trying to get lost value back to stockholders by re-activating the assets at the cost of others and giving a share to stockholders. Hey, stockholders would have been diluted anyway to progress the business. The real lost value is Chippie's decision to can the stem cells and destroy value, lose patent battles in the process.

2.67+0.02(+0.75%)1:55 PMEDT